Nurix Therapeutics

Nurix Therapeutics company information, Employees & Contact Information

At Nurix Therapeutics, we aim to fundamentally change the way disease is treated using degrader-based medicines. Our journey began with a vision to harness the power of the cell’s natural protein degradation machinery, the ubiquitin-proteasome system, to create a new class of therapeutics that can overcome the limitations of current treatments.

Company Details

Employees
368
Founded
-
Address
1700 Owens Street, Suite 205, San Francisco,ca 94158,united States
Phone
415-660-5320
Email
in****@****inc.com
Industry
Biotechnology
HQ
San Francisco, CA
Looking for a particular Nurix Therapeutics employee's phone or email?

Nurix Therapeutics Questions

News

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - The Manila Times

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia The Manila Times

Nurix Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Nurix Therapeutics to Participate in Upcoming Investor Conferences Yahoo Finance

FDA Grants Orphan Drug Designation to Bexobrutideg for Waldenström Macroglobulinemia - Docwire News

FDA Grants Orphan Drug Designation to Bexobrutideg for Waldenström Macroglobulinemia Docwire News

Nurix Therapeutics (Nasdaq: NRIX) 600 mg dose cleared; DAYBreak Phase 2 opens in r/r CLL - Stock Titan

Nurix Therapeutics (Nasdaq: NRIX) 600 mg dose cleared; DAYBreak Phase 2 opens in r/r CLL Stock Titan

Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy - JD Supra

Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy JD Supra

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial - Yahoo Finance

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Yahoo Finance

Degrader-Antibody Conjugates (DACs): Targeted Protein Degradation for Therapeutics - geneonline.com

Degrader-Antibody Conjugates (DACs): Targeted Protein Degradation for Therapeutics geneonline.com

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - Yahoo Finance

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 Yahoo Finance

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 - Yahoo Finance

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 Yahoo Finance

Top Nurix Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant